TARGET PharmaSolutions
Latest round
- Series A
Last raised
- Mar 2016
Total raised
- $2M
Investors
- 2
About TARGET PharmaSolutions
Founded in 2015, TARGET PharmaSolutions, Inc. operates from its headquarters in Durham, US, specializing in developing detailed disease registries. The company was established by Meg Powell and Michael Fried.00 mn through three distinct deals.Target RWE specializes in generating comprehensive longitudinal datasets utilizing advanced analytics and causal inference methodologies. Its core offerings revolve around the development of detailed disease registries, particularly in liver disease, gastroenterology, and dermatology. These registries amalgamate patient and clinician-reported outcomes with biosamples, providing robust insights into disease progression, treatment efficacy, and safety in real-world settings. Target RWE’s services cater to a diverse clientele, including pharmaceutical companies, healthcare providers, and regulatory agencies, primarily in the United States and Europe.Target RWE's revenue is derived from a combination of subscription-based models and partnerships with various stakeholders in the healthcare sector. The company engages with clients through tailored research agreements that leverage its extensive patient registries for real-world evidence generation. These transactions typically involve fees for access to proprietary analytics software, such as causalRisk™ and causalPHR™, as well as services related to regulatory compliance and pharmacovigilance. While specific pricing structures for products and services are not disclosed, the firm’s offerings are designed to meet the needs of its client base while providing comprehensive solutions for new drug applications and post-marketing commitments.TARGET PharmaSolutions, Inc. has plans for future growth that include the development of new products aimed at enhancing its disease registries, though specific release dates have not been disclosed. The company is also targeting geographic expansion into new markets, with a focus on increasing its presence in Europe.
Who invested in TARGET PharmaSolutions
2 investors across 1 round
See all investors in TARGET PharmaSolutions
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Mar 1, 2016
Amount
$2M
Investors
Questions about TARGET PharmaSolutions
Who invested in TARGET PharmaSolutions?
TARGET PharmaSolutions has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has TARGET PharmaSolutions raised?
TARGET PharmaSolutions has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did TARGET PharmaSolutions last raise money?
TARGET PharmaSolutions's most recent round on record is a Series A, in Mar 2016.
What does TARGET PharmaSolutions do?
Founded in 2015, TARGET PharmaSolutions, Inc.
Where is TARGET PharmaSolutions headquartered?
TARGET PharmaSolutions is headquartered in Durham, US.
Which VCs invest in companies like TARGET PharmaSolutions?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at TARGET PharmaSolutions's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like TARGET PharmaSolutions? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.